VentiV Scientific has announced the successful completion of its first-in-human (FIH) clinical cases utilising the V-Pulse mechanical thrombectomy system, a novel thrombectomy platform developed to remove blood clots from the peripheral vasculature.
“The V-Pulse system removed significant clot burden and provided immediate visual confirmation of thrombus capture through its integrated filtration technology,” said Makmood Razavi (St. Joseph Heart & Vascular Center, Orange, USA). “In our initial experience, the device demonstrated excellent control and procedural efficiency. Effective clot removal is critical for patients suffering from venous and arterial thrombotic disease, where delayed treatment can lead to serious complications.”
Unlike conventional aspiration thrombectomy systems that rely solely on continuous vacuum generated by syringes or electromechanical pumps, the V-Pulse system is designed to provide physicians with real-time control over aspiration force at the catheter tip. The V-Pulse technology enables clinicians to rapidly initiate, stop, increase, or decrease aspiration while potentially minimising catheter clogging and reducing procedural blood loss.
“Aspiration thrombectomy systems can remove substantial volumes of blood while attempting to extract thrombus,” said John O’Connor, president of VentiV Scientific. “The V-Pulse platform was engineered to provide physicians with procedural control, optimise aspiration efficiency, and potentially reduce blood loss while remaining compatible with aspiration pumps already available in hospitals today.”
Procedural success depends on multiple factors, including clot age, composition, location, catheter design, and aspiration force, described the company in a recent press release. V-Pulse was developed to address these challenges through a differentiated aspiration-control platform designed to improve clot extraction performance while enhancing procedural control.
The VentiV Scientific thrombectomy portfolio currently includes the US Food and Drug Administration (FDA)-cleared Control Aspire mechanical thrombectomy system, featuring over-the-wire catheters indicated for use in the peripheral vasculature, as well as rapid-exchange catheter systems cleared for use in both peripheral and coronary applications.
In addition to V-Pulse, VentiV Scientific is developing next-generation thrombectomy technologies, including a proprietary multi-strut thrombectomy basket retrieval platform currently under development. These investigational products have not been cleared by the US FDA.
